The New England journal of medicine
The most recent articles from:
N. Engl. J. Med.
-
Comment Letter
Prospective trial of a pediatric ventricular assist device.
-
Historical Article
Repackaging cigarettes--will the courts thwart the FDA?
-
Randomized Controlled Trial Multicenter Study
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
In observational analyses, higher levels of high-density lipoprotein (HDL) cholesterol have been associated with a lower risk of coronary heart disease events. However, whether raising HDL cholesterol levels therapeutically reduces cardiovascular risk remains uncertain. Inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels and might therefore improve cardiovascular outcomes. ⋯ In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events. (Funded by F. Hoffmann-La Roche; dal-OUTCOMES ClinicalTrials.gov number, NCT00658515.).